tiprankstipranks
Mesoblast Director Increases Share Holdings Significantly
Company Announcements

Mesoblast Director Increases Share Holdings Significantly

Story Highlights

Don't Miss Our Christmas Offers:

Mesoblast ( (MESO) ) has shared an update.

Mesoblast Limited has announced a significant change in the holdings of its director, Dr. Eric Rose. On December 13, 2024, Dr. Rose acquired 5,039,814 ordinary shares through a share placement approved by shareholders at the 2024 AGM, increasing his total holdings to 5,451,434 ordinary shares. This acquisition reflects the company’s ongoing strategic maneuvers to strengthen its leadership position and potentially enhance shareholder value.

More about Mesoblast

Mesoblast Limited is a company in the biotechnology sector focused on regenerative medicine, particularly the development of cellular therapies for inflammatory diseases, orthopedics, and cardiovascular conditions. The company leverages its proprietary mesenchymal lineage cell therapy technology to address unmet medical needs.

YTD Price Performance: 565.00%

Average Trading Volume: 322,381

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $1.74B

For detailed information about MESO stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyNordstrom family to take chain private: Morning Buzz
TheFlyPony AI, Thermo Fisher initiated: Wall Street’s top analyst calls
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App